On Monday, the US Supreme Court declined to hear a case brought by six major pharmaceutical companies against the Medicare drug price negotiation program. Novo Nordisk, AstraZeneca, Johnson & Johnson's Janssen unit, Bristol Myers Squibb, Novartis, and Boehringer Ingelheim had challenged the law on constitutional grounds, claiming it violated property rights and free speech protections. The justices offered no explanation for their decision to reject the case. This refusal left in place lower-court rulings that supported the government's authority to negotiate drug prices directly with manufacturers. The negotiation program was created by the Inflation Reduction Act, signed by President Joe Biden in 2022. It represents the first time Medicare has been allowed to negotiate prices with drugmakers. The first set of ten negotiated drug prices took effect this year. Companies that refuse to participate face steep penalties or must remove their medications from both Medicare and Medicaid. Interestingly, despite Republican opposition to the broader law, the current Trump administration has continued and expanded the program. Without a new law from Congress, the negotiation authority will likely remain in place indefinitely. The pharmaceutical industry's legal challenge has failed, and the next round of negotiations is already scheduled to begin.